ONTX vs. ANGN, COCP, ATHX, ATNX, CLRB, CLVR, NNVC, LEXX, AMTI, and GLS
Should you be buying Onconova Therapeutics stock or one of its competitors? The main competitors of Onconova Therapeutics include Angion Biomedica (ANGN), Cocrystal Pharma (COCP), Athersys (ATHX), Athenex (ATNX), Cellectar Biosciences (CLRB), Clever Leaves (CLVR), NanoViricides (NNVC), Lexaria Bioscience (LEXX), Applied Molecular Transport (AMTI), and Gelesis (GLS). These companies are all part of the "pharmaceutical preparations" industry.
Onconova Therapeutics vs.
Angion Biomedica (NASDAQ:ANGN) and Onconova Therapeutics (NASDAQ:ONTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends.
Angion Biomedica has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Onconova Therapeutics has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500.
Onconova Therapeutics has lower revenue, but higher earnings than Angion Biomedica. Angion Biomedica is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.
Given Angion Biomedica's higher possible upside, research analysts clearly believe Angion Biomedica is more favorable than Onconova Therapeutics.
Onconova Therapeutics received 357 more outperform votes than Angion Biomedica when rated by MarketBeat users. However, 64.71% of users gave Angion Biomedica an outperform vote while only 64.68% of users gave Onconova Therapeutics an outperform vote.
17.0% of Angion Biomedica shares are held by institutional investors. Comparatively, 8.3% of Onconova Therapeutics shares are held by institutional investors. 19.7% of Angion Biomedica shares are held by company insiders. Comparatively, 1.2% of Onconova Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Angion Biomedica has a net margin of -81.45% compared to Onconova Therapeutics' net margin of -8,391.15%. Angion Biomedica's return on equity of -22.70% beat Onconova Therapeutics' return on equity.
In the previous week, Onconova Therapeutics had 10 more articles in the media than Angion Biomedica. MarketBeat recorded 11 mentions for Onconova Therapeutics and 1 mentions for Angion Biomedica. Onconova Therapeutics' average media sentiment score of 0.50 beat Angion Biomedica's score of -1.64 indicating that Onconova Therapeutics is being referred to more favorably in the news media.
Summary
Angion Biomedica and Onconova Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ONTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Onconova Therapeutics Competitors List
